{"id":"W1990675339","doi":"10.1016/s0140-6736(14)60958-2","title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","year":2014,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1761,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Ipilimumab; Internal medicine; Clinical endpoint; Adverse effect; Refractory (planetary science); Cohort; Clinical trial; Melanoma; Response Evaluation Criteria in Solid Tumors; Gastroenterology; Surgery; Phases of clinical research; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003245996,0.002845577,0.004221736,0.0004793212,0.0006705007,0.001958917,0.001294077,0.002228184,0.005790249],"category_scores_gemma":[0.002959124,0.001143615,0.003709601,0.0005111485,0.00170421,0.00193308,0.0006283458,0.005429523,0.001357549],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00160424,"about_ca_system_score_gemma":0.001000059,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001122701,"about_ca_topic_score_gemma":0.001805521,"domain_scores_codex":[0.9984131,0.0008461134,0.0000625195,0.0003148354,0.00008754927,0.0002758771],"domain_scores_gemma":[0.9984641,0.0004530211,0.0003526554,0.0002603245,0.00009066597,0.0003791623],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9844892,0.003581092,0.0008329683,0.0001977602,0.001286784,0.0000350673,0.00005075047,0.0003670411,0.002024182,0.00006325534,0.0005351815,0.006536719],"study_design_scores_gemma":[0.9352221,0.05866689,0.003688937,0.00002474521,0.0009776794,0.00004705934,0.00003101922,0.0003174911,0.0003091976,0.0001994389,0.0004932889,0.00002217321],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913381,0.003327304,0.0004754906,0.0005747717,0.0004004033,0.001537157,0.0009232838,0.0000572088,0.001366381],"genre_scores_gemma":[0.9896991,0.001807247,0.0007774161,0.0009167676,0.0004737624,0.002018428,0.001348539,0.00003413305,0.002924635],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005790249,"threshold_uncertainty_score":0.01937038,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03062678598511109,"score_gpt":0.3242064810358412,"score_spread":0.2935796950507301,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}